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IT is reasonableto argue that ifone attempts to control the spread ofcancer by
cytotoxic agents then these should be given by the most appropriate route.
Since many cancers spread by the lymphatic pathways it is logical to consider
infusing such agents into the lymphatics. In a previous paper (Calnan, Rivero,
Fillmore and Mercurius-Taylor, 1967) the permeability of normal lymphatics was
studied, and the present work can be considered an extension ofthis. This study
concerns the disposition of two specific cytotoxic agents, methotrexate and
cyclophosphamide, when infused into lymphatics.
MATERLALS
Methotrexate
This was purchased from the Radiochemical Centre, Amersham. Metho-
trexate labelled in the 3', 5' positions of the phenyl ring is prepared from the
corresponding dichloro compound by a halogen-tritium exchange reaction. The
tritiated methotrexate is purified by chromatography on DEAE cellulose, as
recommended by Johns, Sperti and Burgen (1961) for folic acid. The major
impurities are p-aminobenzoylglutamate and an unidentified pteridine.
Methotrexate is the 4-amino-N10-methyl analogue offolic acid, and appears to
prevent the normal meta-anaphase step in the process of division of the nuclei of
cells.
Folinic acid (5 formyltetrahydrofolic acid) will protect the dividing cell against
the effects of methotrexate (Jacobson, 1966).
The labelled methotrexate has a specific activity of 1x86 me per mg. and a
purity greater than 95 %. It has a molecular weight of 454-5, and is supplied as
the freeze dried sodium salt. Water was added to make the solution required for
use and this is stable for about 3 weeks. In practice all our experiments were
carried out within 2 weeks.
Cyclophosphamide
Cyclophosphamide is a nitrogen mustard (2-di-2-chloroethylamino-1-oxa-3-
aza-2 phosphacylohexane 2-oxide) of molecular weight 261.
The 32P-labelled cyclophosphamide had a specific activity of 1 mc per mm and
was supplied in 5 ml. propylene glycol. Aliquots of this solution were used in
each experiment during a period of two weeks.INTRALYMPHATIC INFUSION OF CYTOTOXIC AGENTS
Experimental animanl
Adult greyhounds, ofmean weight 55 lbs, were used in all experiments because
the peripheral lymphatic trunks are large in these dogs and easy to find, the
thoracic duct is of fairly constant size and position, and the iliac veins are large
enough to accommodate sampling catheters without interference to blood flow.
METHODS
Experimental technique (Fig. 1)
Under general anaesthesia a lymphatic on the dorsum of the hindpaw was
cannulated and a constant infusion of saline at 0-5 ml./minute begun. The
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FIa. 1.-Diagram ofthe experimental design.
thoracic duct was cannulated low down in the left neck and any branches tied
off. Theflowoflymph was measured at 5 minute intervals until it was constant.
Sampling catheters ofpolythene (internal bore 2 mm.) were introduced, by the
Seldinger technique, for 4inches into each femoral vein atthe groin. A venogram,
on rapid injection of 20 ml. 45 % Hypaque (sodium diatroazate) was always done
to confirm that tips of the sampling catheters lay in the common iliac veins and
in identical positions (Fig. 2). If this was not found to be so, adjustments were
made to the catheters and a further X-raytaken. These catheters were connected
to automatic rapid sampling pipettes (Baird & Tatlock, London).
A quantity of the labelled agent (methotrexate 0.5 ml.; cyclophosphamide
0-2 ml.) was introduced by hand into the cannula in the paw lymphatic, marked
by an air bubble fore and aft, and the constant infusion of saline recontinued.
As soon as all the agent had been delivered, samples of blood and lymph were
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taken. Venous blood samples were collected at 30 second intervals, the final
specimen being at 30 minutes. All thoracic duct lymph was collected for 90
minutes in separate pots of 10 minute fractions. All blood and lymph samples
were collected in heparinized bottles, and samples for background values were
taken before each experiment began.
Venous blood flow was measured by the indicator dilution technique of
Shillingford, Bruce and Gabe (1961), using a special catheter with retrograde
injection ports (Kountz, Dempster and Shillingford, 1964) which replaced the
normal sampling catheter ofthe ipsilateral common iliac vein.
Method of counting tritium in plasma (i.e. methotrexate)
Samples of blood and thoracic duct lymph collected in the heparinized tubes
were spun to obtain plasma. From each, 1 ml. of plasma was pipetted off and
transferred to special clean glass bottles containing 10 ml. of Bray scintillation
fluid, when an immediate precipitate of protein was formed. The bottles were
stoppered and shaken vigorously for about 5 seconds, and left to stand for at least
3 hours to allow the precipitate to settle. The bottles were then placed in an
automatic tri-carb liquid scintillation counter, housed in a deep freeze to attain the
working temperature of -8° C. The optimum counting conditions for tritium
in this scintillation fluid were found by repeatedly counting the standard reference
solution at different voltages. The standard solution was made from 1 ml. of a
known dilution ofthe original tritium in 10 ml. ofscintillation fluid.
All bottles were counted for 3 minutes. In some experiments bottles were
countedfor 10 minutes each, butwith no material advantage. Thevaluesrecorded
were corrected to unit time for the volume of each sample.
Method of counting 32P in whole blood (i.e. cyclophosphamide)
Since 32P emits some gamma rays, 3 ml. samples of blood or lymph were
counted for 100 seconds in a conventional well-type scintillation counter with a
sodium iodide crystal.
Experimental design
When a substance, labelled by a radioactive isotope, is placed within a
lymphatic trunk and propelled centrally by a constant infusion ofsaline, then one
of two things may happen.
Ifthe substance does not leak out from the lymphatic then one may expect to
recover it from the cannulated thoracic duct and no radioactivity will be found in
the blood. In this event we may conclude that the lymphatic is impermeable to
the passage through its wall of the test substance. If, however, the substance
does leak through the lymphatic wall, we may recover a portion of it from the
thoracic duct lymph, but we shall also expect to find radioactivity in the blood
from the ipsilateral venous samples due to reabsorption by veins. Ifthe shunt of
radioactivity from lymphatic to vein is large then there will be a rise in activity of
EXPLANATION OF PLATE.
FiG. 2.-Venogram to show identical position of sampling catheters in the common iliac veins.
FiG. 6.-X-ray of popliteal lymph node (arrow) containing all the lipiodol oil after infusion
oflymphatic with cyclophosphamide-lipiodol emulsion.
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the general circulation, demonstrated by increased activity in the contralateral
venous samples.
Ifin addition, the rate ofblood flow at the site ofsampling is known, then it is
possible to make quantitative estimations of the degree of transfer of the test
substance from lymphatic to vein (Pentecost, Burn, Davies and Clalnan, 1966).
RESULTS
Methotrexate
In 3 dogs where methotrexate was infused into a paw lymphatic it was re-
covered in fair quantity from venous blood: a high proportion of this was found
within a few minutes ofinfusion (Fig. 3). In 1 dog in which the lymphatics were
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FIG. 3.-Graph of recovery of methotrexate in dog C/274
after intralymphatic infusion.
IU
all ligated at the groin, methotrexate was recovered from venous blood with equal
speed, but the amount found in thoracic duct lymph was appreciably smaller
(Table I).
TABLE I.-Recovery ofTritium-labelled Methotrexate Infu8ed into
Hind Paw Lymphatic Trunkn
from locE
Dose venous
Dog Side infused blood fo:
number Wt (lbs) Sex infused (PtC) 30 min.
C/190 . 56 . F . L . 2-0 . 34.7%
C/226 . 66 . M . L . 2-3 . 5-6%
(obstructed)
C/274 . 55 . F . R . 2*0 . 52%
C/279 . 66 . M . L . 16 . 43%
Recovery
A
al
from thoracic
r duct lymph
for 90 min.
3.9%
0.1%
3.8%
1*4%
I :.
U
K.
IE6
1-pId
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In a further experiment, methotrexate was infused into the ipsilateral femoral
artery, and as expected the amount found in the femoral vein was large and
immediate. But the total amount recovered was less than 18 % suggesting that
a great deal had become fixed in the tissues (Fig. 4 and Table II).
;blood
0 5 11 20
GREYHOUND 9 41 lbs.
C1275
METHOTREXATE
Blood flow;R.CI.vein
-250 msismin.
Recovery: Blood :18%o
Lymph: 0-2O/o
MINUTES.
FIG. 4.-Graph of recovery of methotrexate in dog C/275
after intra-arterial infusion.
TABLE II. Recovery of Isotope-Labelled Cytotoxic Agents Infused into
Femoral Artery
Dog number
anid aeint
C/275
Methotrexate
C/634
Cyclophosphamicle
wt
(lb)
. 41
Sex
.F
Dose
infuse(d
(2tc)
.2-0.
44 . Al . 40
Recovery
from common
iliac vein from thoracic
blood duct lymph
18%
in 30 min.
780o
in 3 min.
in 90 min.
1.000
in 90 min.
Cyclophosphamide
In 3 similar experiments, cyclophosphamide was recovered in quantity from
local venous blood (Fig. 5 and Table III). On one occasion the agent was mixed
with 1 mnl. of poppy seed oil containing 400% of iodine (Neohydriol) and this
emulsion infused into the lymphatic in an attempt to retard its permeation.
Although the popliteal lymph node demonstrated the presence of the X-ray
contrast medium (Fig. 6) the recovery of cyclophosphamide from local venous
blood was greater than usual and that from thoracic duct lymph less than expected.
In 1 dog when cyclophosphamide was injected into the femoral artery 75 % could
10,000
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FIG. 5.-Graph of recovery of cyclophosphamide in dog
C/599 after intralymphatic infusion.
TABLE III.-Recovery of 32p Labelled Cyclophosphamide Infused into
Hind Paw Lymphatic Trunk
Dog
number
C/599
0/604
C/617
C/626
wt
(lbs)
51
59
40
58
Sex
F
F
F
M
Side
infused
R
L
R
R
Dose
(Oc)
40
40
40
40
in poppy
seed oil
emulsion
Recovery
from local
venous from thoracic
blood for duct lymph
30 min. for 90 min.
74X5% 8-4%
35.6% 18-4%
36% 40%
51.6% 7.4%
be recovered from the ipsilateral common iliac vein within 3 minutes (Fig. 7), in
sharp contrast to the relatively small amount of methotrexate recovered in 30
minutes in an identical experiment (Table II). In both instances only 1% ofthe
total agent placed in the artery was recovered from thoracic duct lymph during
90 minutes.
Tissue concentrations
In 3 experiments in which 32p cyclophosphamide had been infused into a
lymphatic on the hindpaw, the popliteal and iliac lymph nodes in the direct line of
infusion, and nodes from the other side as controls were removed at 90 minutes
and the amount of radiation counted and expressed as counts per g. of tissue.
Biopsies of liver, kidney and spleen were also taken but showed no significant
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FIa. 7.-Graph of recovery of cyclophosphamide after intra-arterial infusion.
activity. Biopsies of skin from the popliteal region always showed significant
radioactivity although the percentage of the total infused was always very small
(Table IV).
TABLE IV.-Tissue Concentration of 32p Cyclophosphamide at 90 Minutes
after Intralymphatic Infusion (Mean of 3 Experiments)
Tissue
A. Infused 8ide
Popiteal skin
Popiteal lymph node .
fliac lymph node
B. Control 8ide
Popiteal skin
Popiteal lymph node
Iliac lymph node
C. Other
Kidney
Spleen
Liver
Counts per g.
of tissue (less
background)
1584
855
243
150
130
44
200
150
140
% of total
infused
0 33
0-17
0*027
0 03
0*02
0-001
0*04
0*03
0-028
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DISCUSSION
Many attempts have been made to establish a technique for intralymphatic
cytotoxic therapy. Jackson, Wallace and Weiss (1962) treated 9 patients by
intralymphatic infusions in saline of cyclophosphamide, 5-fluorouracil and ame-
thopterin but without improvement. They concluded that " lymphatics are
thin-walled structures that do not retain aqueous solutions under pressure ".
Suspension of the solution in oil was not satisfactory. Ariel, Resnick and Galey
(1964) used phenylalanine mustard, thiotepa and methotrexate without benefit
to 4 patients, and concluded that chemotherapeutic drugs given by the lymphatics
fail to be effective, but could not explain this failure. McCarthy, O'Malley and
FitzGerald (1964) used cytotoxic drugs experimentally in rabbits; these were
dissolved in propylene glycol and this solution was then emulsified with lipiodol
before being injected into a lymphatic trunk. They were able to show necrosis of
regional lymph nodes after infusion, and so corrected the earlier conclusions, of
Ariel et al., but did not estimate the amount of drug lost from the lymphatic
system. Battezzati and Donini (1965) in a clinical trail of 114 patients expressed
general approval of the technique.
As Johns, Sperti and Burgen (1961) point out, the " avidity with which folic
acid is removed from plasma by the tissues is quite remarkable ". They noted
that 950 of an injected dose of 1 microgram per kilogram was removed in 3
minutes, suggesting that a high affinity for folic acid must be a property of most
tissues, leading to a high relative concentration offolic acid in cells. Methotrexate
on the other hand was not so rapidly removed and appeared to be restricted
largely to the extracellular space. Indeed this failure to penetrate the intracel-
lular space distinguishes methotrexate from folic acid, suggesting that there is a
specific membrane transport process for folic acid. Certainly the loss of metho-
trexate from the circulation after a single intra-arterial injection is quite remark-
able. Equally large is the loss from lymphatic trunks into blood after
intralymphatic infusion, for which there is no need to postulate special affinity of
the tissues for methotrexate.
Because so many of the cytotoxic agents are relatively insoluble in oils, there
is at present no effective method by which to prevent the ready egress of such
drugs from a lymphatic trunk, particularly when the infusion is intended for a site
at some considerable distance. Certainly when a watery solution is introduced
at the foot, less than 5 % can be recovered from the thoracic duct, which in dogs is
some 60 cm. further along the lymphatic pathway.
Because methotrexate was labelled with the isotope tritium, a pure beta-
emitter, it was not possible technically to show its disposition in tissues. For this
reason the work was repeated with cyclophosphamide labelled by 32p. But the
results of the latter were almost identical and the proportion in various tissues
was small and similar. Moreover when cyclophosphamide in propylene glycol
was emulsified with poppy seed oil, the recovery of clyclophosphamide from blood
was as great as when infused alone, even though all the poppy seed oil was con-
fined to the popliteal node (Fig. 6).
In previous studies we have demonstrated that lymphatic permeability
depends on molecular size, in that substances ofsize smaller than 17,000 are freely
permeable while those of 21,000 and over are not (Calnan, Rivero, Fillmore and
Mercurius-Taylor, 1967). Since all cytotoxic agents are of relatively small
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molecular size in comparison, it is not surprising that they leave lymphatics so
freely. From the evidence of our experiments it is clear that cytotoxic drugs
given intralymphatically cannot offer any special advantage in the treatment of
malignant disease.
This form of therapy may have a rational basis if cytotoxic drugs of much
larger molecular size can be found or their polymers prepared. Alternatively a
drug of smaller molecular size may be bound chemically or physically to a sub-
stance oflarge molecular size in the hope that this bond will break down when the
agent reaches the site of the required effect.
SUMMARY
1. Methotrexate and cyclophosphamide, labelled with radioactive isotopes,
were infused into a lymphatic on the hindpaw of 8 dogs. In 2 dogs these agents
were placed in the regional artery. Radioactivity was measured in samples of
blood and lymph.
2. Both drugs were found to diffuse freely from the lymphatic trunks.
3. On present evidence it would appear that cytotoxic drugs given by a
lymphatic route can offer no particular advantage in the treatment of malignant
disease.
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